Delphine Breuillard

Delphine Breuillard

Auto-generated profile, based on publicly available information

Delphine Breuillard

Reference Center for Rare Epilepsies, Department of Pediatric Neurology, Necker Enfants Malades Hospital, APHP, full member of the European Reference Network EpiCARE Université Paris Cité Paris France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2024 in Epilepsia
Verified
Journal Article
Open access
RNRima Nabbout
Rima Nabbout
AMAgathe Molimard
Agathe Molimard
GSGiovanna Scorrano
Giovanna Scorrano
MAMelodie Aubart
Melodie Aubart
DBDelphine Breuillard
Delphine Breuillard
IDIsabelle Desguerre
Isabelle Desguerre
Objective: Complex epilepsies such as epileptic and developmental encephalopathies require multidisciplinary care throughout life. A coordinated transition program is therefore essential to provide optimal support for patients leaving pediatric for adult care. The aim of this study is to describe and evaluate our transition program for complex epilepsies, focusing on the last step in this program, that is, the multidisciplinary transition day hospital (MTDH).Methods: We performed a retrospective observational study including patients with complex epilepsies who underwent the full steps of the transition program at Necker–Enfants Malades Hospital between May 2021 and June 2023, with a follow‐up until February 2024. We described the cohort and detailed the interventions performed during the MTDH including medical, medicosocial, educational, daily life abilities, and laboratory and imaging assessments with the participation of one member of the adult team.We evaluated two indicators of our program: (1) the “adult first clinic attendance rate,” defined by the percentage of patients attending their first adult clinic; and (2) the “return rate,” defined by the percentage of patients who requested a pediatric encounter after their transfer.Results: Our cohort included 70 patients with a mean age of 19.1 years (interquartile range = 16.3–19.5). Eighty percent had an epilepsy syndrome diagnosis; 72.8% were treated with three or more antiseizure medications. All patients had their appointment at the adult clinic within 6 months of the day hospital, and only two families requested a pediatric encounter after the transfer.Significance: The transition program is key for an optimal transfer of patients with complex epilepsies to adult care. It requires a comprehensive multidisciplinary approach and provides a complete summary of the medical record. Our program secures a smooth landing in adult care and is a promising model to better manage the challenging transition process, especially in patients with complex epilepsy.

1 February 2025 in Epilepsia Open
Verified
Journal Article
Open access
ABAndreas Brunklaus
Andreas Brunklaus
SSSusanne Schubert‐Bast
Susanne Schubert‐Bast
FDFrancesca Darra
Francesca Darra
KNKatherine Nickels
Katherine Nickels
DBDelphine Breuillard
Delphine Breuillard
RSRocío Sánchez‐Carpintero
Rocío Sánchez‐Carpintero
Objective: Dravet syndrome is a developmental and epileptic encephalopathy characterized by drug‐resistance, lifelong seizures, and significant comorbidities including intellectual and motor impairment. Receiving a diagnosis of Dravet syndrome is challenging for parents/caregivers, and little research has focused on how the diagnosis should be given. A Delphi consensus process was undertaken to determine key aspects for healthcare professionals (HCPs) to consider when communicating a Dravet syndrome diagnosis to parents/caregivers.Methods: Following a literature search and steering committee review, 34 statements relating to the first diagnosis consultation were independent‐ and anonymously voted on (from 1, totally inappropriate, to 9, totally appropriate) by an international group of expert child neurologists, neuropsychiatrists, nurses, and patient advisory group (PAG) representatives. The statements were divided into five chapters: (i) communication during the first diagnosis consultation, (ii) information to be delivered during the first diagnosis consultation, (iii) points to be reiterated at the end of the first diagnosis consultation, (iv) information to be delivered at subsequent consultations, and (v) communication around genetic testing. Statements receiving ≥ 75% of the votes with a score of ≥7 and/or with a median score of ≥8 were considered consensual.Results: The statements were evaluated by 44 HCPs and PAG representatives in the first round of voting; 29 statements obtained strong consensus, 3 received good consensus, and 2 did not reach consensus. The committee reformulated and resubmitted 4 statements for evaluation (42/44 voters): 3 obtained strong consensus and 1 remained not consensual. The final consensual recommendations include guidance on consultation setting, key disease aspects to convey, how to discuss genetic testing results, disease evolution, and the risk of SUDEP, among other topics.Significance: It is hoped that this international Delphi consensus will facilitate a better‐structured initial diagnosis consultation and offer further support for parents/caregivers at this challenging time of learning about Dravet syndrome.Plain Language Summary: Diagnosis of Dravet syndrome, a rare and severe form of childhood‐onset epilepsy, is often challenging to give to parents. This international study developed guidance and recommendations to help healthcare professionals better structure and personalize this disclosure. By following this advice, doctors can provide more tailored support to families, improving their understanding and management of the condition.

3 May 2016 in Neurology
Verified
Journal Article
Open access
PDF file
MHMarie Hully
Marie Hully
DGDavid Grevent
David Grevent
DBDelphine Breuillard
Delphine Breuillard
FBFrancis Brunelle
Francis Brunelle
NCNicole Chemaly
Nicole Chemaly
RNRima Nabbout
Rima Nabbout

21 May 2026 in Epilepsia Open
Verified
Journal Article
Open access
GSGiovanna Scorrano
Giovanna Scorrano
DBDelphine Breuillard
Delphine Breuillard
ATAnais Thimon
Anais Thimon
NCNicole Chemaly
Nicole Chemaly
RNRima Nabbout
Rima Nabbout
Objectives: Sleep disturbances are frequent comorbidities in epilepsies and developmental encephalopathies. This study aimed to characterize sleep abnormalities in individuals with KCNB1 ‐related disorders, focusing on their prevalence, clinical manifestations, and impact on daily functioning. Methods: We included individuals with KCNB1 ‐related disorders through a collaboration with KCNB1 association. Genetic, clinical, and electroencephalographic (EEG) data were collected. Caregivers completed the Sleep Disturbance Scale for Children (SDSC) and the 22‐item Children's Sleep Habits Questionnaire (CSHQ) to assess sleep profiles. Results: Seventy‐eight patients were enrolled (42 males, 36 females; mean age 13.7 ± 9.3 years, median 11). At least one abnormal SDSC subscale score was identified in 53/78 individuals (67.9%). Disorders of initiating or maintaining sleep (DIMS) were the most frequent disorders (38/53, 71.7%). In the epilepsy subgroup, sleep problems were more common among patients receiving polytherapy (≥2 ASMs) and those with frequent seizures. Sleep disturbances were reported in 13 of 18 individuals with developmental encephalopathy (DE) (72.2%) and in 17 of 57 individuals with developmental and epileptic encephalopathy (DEE) (29.8%). Significance: Sleep disturbances are highly prevalent in KCNB1 ‐related disorders. Comprehensive and individualized care is essential to enhance quality of life and optimize seizure and developmental outcomes. Plain Language Summary: In this study, we characterize sleep disturbances in individuals with KCNB1‐related disorders. Sleep disorders are highly prevalent in this population and can significantly impact daily functioning of the patient and his family. Early identification and personalized management are key to improving quality of life, optimizing seizure control, and supporting developmental outcomes.

18 August 2026 in Epilepsia
Verified
Journal Article
Open access
PDF file
BBBernardo Dalla Bernardina
Bernardo Dalla Bernardina
FOFrancesca Offredi
Francesca Offredi
ATAlessio Toraldo
Alessio Toraldo
LOLisa Ouss
Lisa Ouss
DBDelphine Breuillard
Delphine Breuillard
RNRima Nabbout
Rima Nabbout
Objective: The Dravet Disease‐Associated Neuropsychiatric Disorders (D‐DAND) scale is a new caregiver‐administered interview designed to assess the wide range of developmental and behavioral comorbidities in Dravet syndrome (DS) beyond seizures. D‐DAND's preliminary psychometric properties in a large patient sample are reported. Methods: D‐DAND was developed by a panel of experts and later standardized with caregivers of 123 individuals with DS (age = 3–41 years); a subsample of 43 caregivers were interviewed twice (~2 weeks apart) to evaluate test–retest reliability; another subsample of 80 were also administered with other scales that are widely used despite not being tailored to DS (Vineland Adaptive Behavior Scales, Child Behavior Checklist, Childhood Autism Rating Scale, Behavior Rating Inventory of Executive Function, Sleep Disturbance Scale for Children). Results: The D‐DAND captured a broad spectrum of abilities and dysfunctions across multiple functional domains. Test–retest reliability was excellent (overall score: r ≈ .98, median across domains: r ≈ .89), thus allowing for high sensitivity to time‐related changes. As expected, D‐DAND scores showed high correlations with some standardized measures (e.g., Vineland scales) and low correlation with others, suggesting that D‐DAND measures unique, Dravet‐specific features that other, widely used tools fail to detect. Significance: D‐DAND is a novel, reliable tool for comprehensive evaluation of DS beyond seizures. It enables systematic tracking of developmental and behavioral issues in DS, facilitating early identification of needs and more personalized, whole‐person care.